Navigation Links
Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials

is designed, studied and manufactured by Abbott Vascular. Abbott supplies a private-labeled version of XIENCE V to Boston Scientific, called the PROMUS(TM) Everolimus-Eluting Coronary Stent System, as part of a distribution agreement established between the two companies last year.

About the SPIRIT Family of Trials

SPIRIT FIRST is a randomized trial comparing the XIENCE V Everolimus Eluting Coronary Stent System with the MULTI-LINK VISION metallic stent system. SPIRIT II was a randomized clinical trial evaluating XIENCE V versus TAXUS in Europe and Asia Pacific. Professor Patrick Serruys of Rotterdam is the principal investigator in SPIRIT FIRST and SPIRIT II.

SPIRIT III is a large-scale randomized pivotal clinical trial comparing XIENCE V to TAXUS in the United States and Japan. SPIRIT IV is a randomized trial currently enrolling patients and will evaluate the safety and efficacy of XIENCE V for the treatment of coronary artery disease in a more complex patient population in the United States. Professor Gregg Stone of Medical Center, N.Y., is the principal investigator in SPIRIT III and SPIRIT IV.

SPIRIT V is an international clinical trial currently enrolling patients that will provide additional data on clinical experience with XIENCE V at 100 clinical sites throughout Europe, Asia, Canada and Latin America.

SPIRIT WOMEN is the world's first drug-eluting stent trial to study only women and will evaluate the characteristics of women undergoing stent implantation as well as the performance of XIENCE V in those patients in Europe, Asia-Pacific, Canada and Latin America.

For images of Abbott's investigational XIENCE V stent system and other information, please visit the company's online newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care bu
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... Wash. and VANCOUVER , ... OGXI ) announced today that it will report its ... 2015. Company management will host a conference call and ... an overview of financial results, clinical development programs and ... the webcast, log on to the Investor Relations page ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... MAY 22, 2012 ThermoGenesis Corp. (NASDAQ: ... the processing, storage and administration of cell therapies, today ... its AXP® AutoXpress® Platform (AXP) used for the processing ... initiate commercial activities in the country later this year. ...
... Holdings, Inc., the tenth largest workers, compensation insurer ... from Medco Health Solutions to Express Scripts as their ... analytics capabilities and insights generated by its team of ... waste and help improve outcomes for injured workers ...
Cached Medicine Technology:ThermoGenesis Announces Axp Approval In Thailand 2ThermoGenesis Announces Axp Approval In Thailand 3Accident Fund Holdings Aims to Improve Control of Drug Utilization and Quality of Care with Change in Pharmacy Benefit Manager 2
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source for ... Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... for the annual Lollapalooza. This unique and unbelievably popular festival attracts the best ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The 2nd ... Church Park in Downtown Memphis on October 3, 2015. The Ride to Fight On ... on cancer research between Methodist Healthcare, The West Clinic and The University of Tennessee ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin and ... their social media profiles to better connect with the public. The agency website ... information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide ...
(Date:7/31/2015)... ... ... article published July 27 on My News LA, a fire that broke out ... fire department before it caused major damage throughout the building. The article also notes that ... a fire alarm system that tipped off fire fighters so they could arrive at the ...
(Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic ... potential patients alike on various plastic surgery procedures including, but not limited to, ... popular dermatology procedures like Botox and fillers. , Staying up to date ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2
... Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused ... to treat inflammatory disease, announced today that Robert Baltera, ... the Montgomery Healthcare Conference 2009 in Menlo Park, Calif., ... 2005 and headquartered in San Diego, Amira Pharmaceuticals is ...
... NEW YORK, Oct. 6 TechCrunch50 2009 Finalist Glide ... announced today a partnership to deploy the Glide Health ... group practice in the United States, with over 100 ... million patients. , Glide Health is the complete ...
... Research Center, Group Health Research Institute and the ... Pharmacy have been selected to lead four projects ... funding for comparative-effectiveness research in cancer. The grants ... such research, which aims to objectively analyze cancer ...
... (SRS) and whole brain radiation therapy (WBRT) for the treatment ... of developing learning and memory problems than those treated with ... M. D. Anderson Cancer Center. The findings of the ... 2009 online edition of the Lancet Oncology . Led ...
... San Diego, CA Nearly all patients who underwent ... obstructive sleep apnea (OSA), according to new research presented ... Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, in ... collected data from 22 patients treated for oropharyngeal cancer, ...
... used for applications that include inventory management, package ... security. More recently, these systems have found their ... assets and staff members. However, there is ... manufacturers of RFID equipment or medical devices can ...
Cached Medicine News:Health News:Glide Health Corporation and Integrated Medical Professionals Announce Partnership to Deploy the Glide Mobile Health Platform to Over One Million Patients and Over 100 Physicians in 50 Locations 2Health News:$16M in stimulus funding launches Seattle as a hub of comparative-effectiveness research in cancer 2Health News:$16M in stimulus funding launches Seattle as a hub of comparative-effectiveness research in cancer 3Health News:$16M in stimulus funding launches Seattle as a hub of comparative-effectiveness research in cancer 4Health News:$16M in stimulus funding launches Seattle as a hub of comparative-effectiveness research in cancer 5Health News:Stereotactic radiosurgery preferred method of treating cancer patients with brain metastases 2Health News:Stereotactic radiosurgery preferred method of treating cancer patients with brain metastases 3Health News:GTRI is developing protocols for testing effects of RFID systems on medical devices 2Health News:GTRI is developing protocols for testing effects of RFID systems on medical devices 3
Liquichek Whole Blood Volatiles Control is an assayed liquid control for monitoring volatile compounds. This product is available in 2 levels....
qUAntify Plus Control is a combination urine dipstick and microscopic control. The control is available in either 12 mL centrifuge tubes or 120 mL flip-top squeeze bottles....
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers....
Lyphochek Hypertension Markers Control is a trilevel control designed to monitor the performance of testing procedures for renin and other analytes associated with hypertension disorders....
Medicine Products: